How the diversification of the business across new challenge models and the expansion of the scope of its services is underpinning scalable growth.

Real world examples of how human challenge models are accelerating the drug delivery process at large biopharma companies.

The success in scaling up the business, including recent news of a new facility to conduct human challenge trials to be opened

How a focus on operational efficiency is driving margin expansion, and the impact of the new facility

The strong outlook with revenue visibility stretching well into 2024, and what’s behind the upgrade of sales and profit outlook, and introduction of a new regular dividend.